Leerink Partners cut shares of Bristol Myers Squibb (NYSE:BMY – Free Report) from an outperform rating to a market perform rating in a research note published on Monday morning, MarketBeat reports. They currently have $59.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $73.00. BMY has been the topic […]